Last reviewed · How we verify
Brentuximab Vedotin (Bv)
Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death.
Brentuximab vedotin is an antibody-drug conjugate that binds to CD30 on tumor cells and delivers a microtubule-disrupting toxin to induce cell death. Used for Hodgkin lymphoma (relapsed or refractory), Systemic anaplastic large cell lymphoma (relapsed or refractory), Primary cutaneous anaplastic large cell lymphoma.
At a glance
| Generic name | Brentuximab Vedotin (Bv) |
|---|---|
| Also known as | BV, Adcetris |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Antibody-drug conjugate (ADC) |
| Target | CD30 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The drug consists of a chimeric anti-CD30 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule-disrupting agent. Upon binding to CD30-expressing cells, the conjugate is internalized and the toxin is released intracellularly, causing mitotic arrest and apoptosis. This targeted delivery mechanism allows concentration of cytotoxic activity in CD30-positive tumor cells while minimizing systemic toxicity.
Approved indications
- Hodgkin lymphoma (relapsed or refractory)
- Systemic anaplastic large cell lymphoma (relapsed or refractory)
- Primary cutaneous anaplastic large cell lymphoma
- Mycosis fungoides (cutaneous T-cell lymphoma)
Common side effects
- Peripheral neuropathy
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Fatigue
- Fever
- Infusion-related reactions
Key clinical trials
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
- BV-CHP Real-life and Biological Evidences in Patients With sALCL
- Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma (PHASE2)
- Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) (PHASE3)
- Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment (PHASE2)
- BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas (PHASE3)
- Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brentuximab Vedotin (Bv) CI brief — competitive landscape report
- Brentuximab Vedotin (Bv) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI